Heidelberg Pharma AG today reported on the first three months of fiscal year 2025 (1 December 2024 – 28 February 2025) and the Group’s financial figures.
– Cohort 7 of the clinical trial of HDP-101 in multiple myeloma safe and well tolerated; Cohort 8 expected to start soon
– Clinical development of the second ADC program HDP-102 in patients with non-Hodgkin lymphoma (NHL) has started
– Amendment of contract with HealthCare Royalty; payment of USD 20 million significantly extends cash reach